SHANGHAI/SUZHOU, China, June 2, 2021. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today announced that Dr. Darren Ji, Co-Founder and Chief Executive Officer of Elpiscience, will present an update on company status and R&D pipeline at the Jefferies 2021 Healthcare Conference at 8:30 p.m. Asia/Shanghai Time on Friday, June 4, 2021.
A live webcast of the Presentation can be retrieved through the link as below:
Elpiscience is a clinical stage biopharmaceutical company focusing on innovating and developing the next generation of cancer immunotherapy. Elpiscience has developed a pipeline of 15 globally innovative molecules, covering a wide range of targets with a particular focus on turning “cold” into “hot” tumors. The company currently has three assets in clinical trials (ES101, ES102 and ES104), three in IND-enabling stage (ES002, ES014 and ES004). Elpiscience’s sustainable pipeline forms a strong cornerstone for developing the next generation and more effective immunotherapies. Founded and managed by seasoned executives in the biopharma industry, Elpiscience is backed by close to 20 top investors such as Lilly Asia Ventures, Hillhouse Capital, Hyfinity Investments and Great Bay Area Development Fund.